RT Journal Article SR Electronic(1) A1 Burgers, Wendy A. A1 Ginbot, Zekarias A1 Shen, Yen-Ju A1 Chege, Gerald K. A1 Soares, Andreia P. A1 Müller, Tracey L. A1 Bunjun, Rubina A1 Kiravu, Agano A1 Munyanduki, Henry A1 Douglass, Nicola A1 Williamson, Anna-LiseYR 2014 T1 The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques JF Journal of General Virology, VO 95 IS 10 SP 2267 OP 2272 DO https://doi.org/10.1099/vir.0.067835-0 PB Microbiology Society, SN 1465-2099, AB Poxvirus vectors represent promising human immunodeficiency virus (HIV) vaccine candidates and were a component of the only successful HIV vaccine efficacy trial to date. We tested the immunogenicity of a novel recombinant capripoxvirus vector, lumpy skin disease virus (LSDV), in combination with modified vaccinia Ankara (MVA), both expressing genes from HIV-1. Here, we demonstrated that the combination regimen was immunogenic in rhesus macaques, inducing high-magnitude, broad and balanced CD4+ and CD8+ T-cell responses, and transient activation of the immune response. These studies support further development of LSDV as a vaccine vector., UL https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.067835-0